TY - JOUR
T1 - NKG2D and DNAM-1 Ligands
T2 - Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
AU - Fionda, Cinzia
AU - Soriani, Alessandra
AU - Zingoni, Alessandra
AU - Santoni, Angela
AU - Cippitelli, Marco
PY - 2015
Y1 - 2015
N2 - A pivotal strategy to improve NK cell-mediated antitumor activity involves the upregulation of activating ligands on tumor cells. Enhancement of NK cell-mediated recognition of multiple myeloma cells was reported by us and others showing increased surface expression of NKG2D and DNAM-1 ligands on tumor cells following treatment with a number of chemotherapeutic agents, such as genotoxic drugs or inhibitors of proteasome, histone deacetylases, GSK3, and HSP-90. These compounds have the capability to affect tumor survival but also to activate specific transduction pathways associated with the upregulation of different NK cell activating ligands on the tumor cells. Here, we will summarize and discuss the molecular pathways whereby these drugs can regulate the expression of NK cell activating ligands in multiple myeloma cells.
AB - A pivotal strategy to improve NK cell-mediated antitumor activity involves the upregulation of activating ligands on tumor cells. Enhancement of NK cell-mediated recognition of multiple myeloma cells was reported by us and others showing increased surface expression of NKG2D and DNAM-1 ligands on tumor cells following treatment with a number of chemotherapeutic agents, such as genotoxic drugs or inhibitors of proteasome, histone deacetylases, GSK3, and HSP-90. These compounds have the capability to affect tumor survival but also to activate specific transduction pathways associated with the upregulation of different NK cell activating ligands on the tumor cells. Here, we will summarize and discuss the molecular pathways whereby these drugs can regulate the expression of NK cell activating ligands in multiple myeloma cells.
UR - http://www.scopus.com/inward/record.url?scp=84934300385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934300385&partnerID=8YFLogxK
U2 - 10.1155/2015/178698
DO - 10.1155/2015/178698
M3 - Article
AN - SCOPUS:84934300385
VL - 2015
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 178698
ER -